s12933-022-01575-9.pdf (5.64 MB)
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
journal contributionposted on 2022-10-27, 15:03 authored by Melanie J Davies, Heinz Drexel, Francois R Jornayvaz, Zoltan Pataky, Petar M Seferovic, Christoph Wanner
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with type 2 diabetes (T2D). Historical concerns about cardiovascular (CV) risks associated with certain glucose-lowering medications gave rise to the introduction of cardiovascular outcomes trials (CVOTs). Initially implemented to help monitor the CV safety of glucose-lowering drugs in patients with T2D, who either had established CVD or were at high risk of CVD, data that emerged from some of these trials started to show benefits. Alongside the anticipated CV safety of many of these agents, evidence for certain sodium–glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revealed potential cardioprotective effects in patients with T2D who are at high risk of CVD events. Reductions in 3-point major adverse CV events (3P-MACE) and CV death have been noted in some of these CVOTs, with additional benefits including reduced risks of hospitalisation for heart failure, progression of renal disease, and all-cause mortality. These new data are leading to a paradigm shift in the current management of T2D, with international guidelines now prioritising SGLT2 inhibitors and/or GLP-1 RAs in certain patient populations. However, clinicians are faced with a large volume of CVOT data when seeking to use this evidence base to bring opportunities to improve CV, heart failure and renal outcomes, and even reduce mortality, in their patients with T2D. The aim of this review is to provide an in-depth summary of CVOT data—crystallising the key findings, from safety to efficacy—and to offer a practical perspective for physicians. Finally, we discuss the next steps for the post-CVOT era, with ongoing studies that may further transform clinical practice and improve outcomes for people with T2D, heart failure or renal disease.
Author affiliationDiabetes Research Centre, College of Life Sciences, University of Leicester
- VoR (Version of Record)
Published inCardiovascular Diabetology
Science & TechnologyLife Sciences & BiomedicineCardiac & Cardiovascular SystemsEndocrinology & MetabolismCardiovascular System & CardiologyCardiovascular diseaseCardiovascular outcomes trialsChronic kidney diseaseCVOTsCardiovascular safetyHeart failureGlucose-lowering drugGLP-1 RAsType 2 diabetesSGLT2 inhibitorsGLP-1 RECEPTOR AGONISTSCHRONIC KIDNEY-DISEASEGLUCOSE COTRANSPORTER-2 INHIBITORSREDUCED EJECTION FRACTIONBASE-LINE CHARACTERISTICSSGLT2 INHIBITORSHEART-FAILURECARDIORENAL PROTECTIONRENAL OUTCOMESLOWERING DRUGS